快速连接 发送消息
In a latest development, Emergency use approval has been granted in India for anti – COVID-19 therapeutic application of the key Active Pharmaceutical Ingredient, 2-deoxy-D-glucose ( 2DG) developed by INMAS, a lab of DRDO, in collaboration with Dr. Reddy’s laboratories.
原料药和服务部首席执行官迪帕克•萨普拉于2021年5月17日在亚洲国际新闻社（ANI）新闻发表讲话，阐明了2DG是一种口服抗病毒药物，只能根据处方派发给住院的中重度新冠病毒病病人服用，与现有的标准护理一起作为辅助（附加）疗法。He said 他说道，印度国防研究与发展组织的抗新冠病毒2DG药是一种附加药物，而不是其他药物的替代品。 点击这里阅读完整回复。
No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.
+91 4049002253